Non Clinical Trials Market - 2022-2030
The Non Clinical Trials Market was valued at US$ 11.5 billion in 2022 and is anticipated to reach US$ 15.3 billion by 2030, at a CAGR of 0.045 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Non Clinical Trials Market.
This report delivers a comprehensive overview of the Non Clinical Trials Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Non Clinical Trials Market. The Non Clinical Trials Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2022–2030.
Non Clinical Trials Market Scope:
By Study Type
This report delivers a comprehensive overview of the Non Clinical Trials Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Non Clinical Trials Market. The Non Clinical Trials Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2022–2030.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Non Clinical Trials Market.
This report delivers a comprehensive overview of the Non Clinical Trials Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Non Clinical Trials Market. The Non Clinical Trials Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2022–2030.
Non Clinical Trials Market Scope:
By Study Type
- Pharmacodynamics (PD) studies
- Pharmacokinetics (PK) studies
- Toxicology studies
- In silico
- In vitro
- In vivo
- Oncology
- Cardiovascular
- Neurology
- Immunology
- Others
- Pharmaceutical and Biotechnology Companies s
- Contract Research Organizations (CROs)
- Academic and Government Research Institutes
- Others
- Labcorp Drug Development
- Charles River Laboratories
- PPD (Pharmaceutical Product Development)
- ICON plc
- Novartis AG
- Merck & Co., Inc.
- AstraZeneca plc
- CMIC HOLDINGS Co., LTD
- ProPharma
- MorphoSys AG
This report delivers a comprehensive overview of the Non Clinical Trials Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Non Clinical Trials Market. The Non Clinical Trials Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2022–2030.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Increase Your Customer Base by 3X using our Partner Identification tool
- Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
- Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
- Prioritize partners by strategic fit rather than general capability.
- Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
- Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
- White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
- Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
- Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
- Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Study Type
3.2. Snippet by Test
3.3. Snippet by Therapeutic Area
3.4. Snippet by End User
3.5. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The rising prevalence of Group B Streptococcus
4.1.1.2. The rising the clinical trials on Group B Streptococcus
4.1.2. Restraints
4.1.2.1. Extensive testing and documentation can often result in delays
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. COVID-19 ANALYSIS
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. BY STUDY TYPE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
7.1.2. Market Attractiveness Index, By Study Type
7.2. Pharmacodynamics (PD) studies *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Pharmacokinetics (PK) studies
7.4. Toxicology studies
8. BY TEST
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
8.1.2. Market Attractiveness Index, By Test
8.2. In silico *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. In vitro
8.4. In vivo
9. BY THERAPEUTIC AREA
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
9.1.2. Market Attractiveness Index, By Therapeutic Area
9.2. Oncology *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Cardiovascular
9.4. Neurology
9.5. Immunology
9.6. Others
10. BY END USER
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.1.2. Market Attractiveness Index, By End User
10.2. Pharmaceutical and Biotechnology Companies s*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Contract Research Organizations (CROs)
10.4. Academic and Government Research Institutes
10.5. Others
11. BY REGION
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.2.6.1. U.S.
11.2.6.2. Canada
11.2.6.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.8.1. Germany
11.3.8.2. UK
11.3.8.3. France
11.3.8.4. Italy
11.3.8.5. Spain
11.3.8.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12. COMPETITIVE LANDSCAPE
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. COMPANY PROFILES
13.1. Labcorp Drug Development *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Charles River Laboratories
13.3. PPD (Pharmaceutical Product Development)
13.4. ICON plc
13.5. Novartis AG
13.6. Merck & Co., Inc.
13.7. AstraZeneca plc
13.8. CMIC HOLDINGS Co., LTD
13.9. ProPharma
13.10. MorphoSys AG (*LIST NOT EXHAUSTIVE)
14. APPENDIX
14.1. About Us and Services
14.2. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Study Type
3.2. Snippet by Test
3.3. Snippet by Therapeutic Area
3.4. Snippet by End User
3.5. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The rising prevalence of Group B Streptococcus
4.1.1.2. The rising the clinical trials on Group B Streptococcus
4.1.2. Restraints
4.1.2.1. Extensive testing and documentation can often result in delays
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. COVID-19 ANALYSIS
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. BY STUDY TYPE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
7.1.2. Market Attractiveness Index, By Study Type
7.2. Pharmacodynamics (PD) studies *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Pharmacokinetics (PK) studies
7.4. Toxicology studies
8. BY TEST
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
8.1.2. Market Attractiveness Index, By Test
8.2. In silico *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. In vitro
8.4. In vivo
9. BY THERAPEUTIC AREA
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
9.1.2. Market Attractiveness Index, By Therapeutic Area
9.2. Oncology *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Cardiovascular
9.4. Neurology
9.5. Immunology
9.6. Others
10. BY END USER
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.1.2. Market Attractiveness Index, By End User
10.2. Pharmaceutical and Biotechnology Companies s*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Contract Research Organizations (CROs)
10.4. Academic and Government Research Institutes
10.5. Others
11. BY REGION
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.2.6.1. U.S.
11.2.6.2. Canada
11.2.6.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.8.1. Germany
11.3.8.2. UK
11.3.8.3. France
11.3.8.4. Italy
11.3.8.5. Spain
11.3.8.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12. COMPETITIVE LANDSCAPE
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. COMPANY PROFILES
13.1. Labcorp Drug Development *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Charles River Laboratories
13.3. PPD (Pharmaceutical Product Development)
13.4. ICON plc
13.5. Novartis AG
13.6. Merck & Co., Inc.
13.7. AstraZeneca plc
13.8. CMIC HOLDINGS Co., LTD
13.9. ProPharma
13.10. MorphoSys AG (*LIST NOT EXHAUSTIVE)
14. APPENDIX
14.1. About Us and Services
14.2. Contact Us
